BreezeMeds Review

BreezeMeds — Provider Profile

Overview

BreezeMeds is a telehealth platform that offers both injectable and oral compounded GLP-1 formulations — a combination that most competitors do not provide. The platform serves all 50 states with an online-only consultation process, and distinguishes itself through named physician leadership and published pharmacy partnerships.

BreezeMeds offers oral semaglutide and oral tirzepatide alongside the standard injectable options — relevant for patients who cannot or prefer not to self-inject. The company also names its medical directors (Dr. Ana Lisa Carr MD and Dr. Kelly Tenbrink MD) and its compounding pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx), a level of transparency uncommon among compounded GLP-1 providers.

Trade-off: medication delivery takes approximately 2–3 weeks from initial consultation, longer than the roughly one-week timeline common among competitors.

April 2026 context: BreezeMeds prescribes exclusively compounded medications — semaglutide and tirzepatide in both injectable and oral forms. Compounded GLP-1s are not FDA-approved. The FDA has been actively taking enforcement action against certain compounders and continues to pressure the sector. Patients choosing any compounded GLP-1 pathway should weigh the regulatory environment. BreezeMeds' multiple pharmacy partnerships provide some supply chain resilience, though they do not change the fundamental regulatory status of compounded medications.

Medications Offered

• Compounded injectable semaglutide — Not FDA-approved
• Compounded oral semaglutide — Not FDA-approved; for patients who prefer not to inject
• Compounded injectable tirzepatide — Not FDA-approved
• Compounded oral tirzepatide — Not FDA-approved; for patients who prefer not to inject
• NAD+ injections
• No brand-name FDA-approved options available

All medications are compounded. No FDA-approved supply chain is offered.

Pharmacy partners: Belmar, Strive, Epiq Scripts, Casa Pharma Rx. Multiple partnerships are intended to provide supply chain redundancy.

Pricing

Injectable tirzepatide pricing is not prominently published on the site — patients should confirm current pricing directly with BreezeMeds.

All plans are FSA/HSA eligible. No subscription required — patients can order on a month-to-month basis.

Oral formulations carry a significant price premium: $299/mo for oral semaglutide and $399/mo for oral tirzepatide are among the higher prices in the compounded market. The premium reflects the less common formulation, but patients should confirm whether oral delivery is necessary for their situation before paying the markup.

States Served

All 50 states.

Insurance

• Insurance: Not accepted — cash-pay only
• FSA/HSA: Eligible

Consultation Process

1. Complete a 100% online health assessment
2. A licensed provider reviews your submission
3. Prescription sent to one of BreezeMeds' partner pharmacies
4. Medication shipped with expedited delivery

Timeline: Approximately 2–3 weeks from initial consultation to receiving medication. This is notably longer than most competitors, many of whom deliver within approximately one week. Patients who need medication quickly should account for this delay.

Pros

• Oral formulations for both semaglutide and tirzepatide — rare among GLP-1 providers
• Named physician leadership (Dr. Ana Lisa Carr MD, Dr. Kelly Tenbrink MD) — transparency uncommon in this space
• Four named pharmacy partners — supply chain redundancy reduces shortage risk
• All 50 states served
• 24/7 support and coaching
• FSA/HSA eligible
• No subscription required
• Claims 50,000+ patient network

Cons

• 2–3 week delivery timeline is significantly slower than most competitors (~1 week)
• All medications are compounded — no FDA-approved option available
• Compounded GLP-1s face active FDA enforcement pressure; supply and legal landscape can change
• Oral semaglutide ($299/mo) and oral tirzepatide ($399/mo) are among the most expensive options in the compounded market
• Injectable tirzepatide pricing not prominently published
• Cash-pay only; no insurance pathway
• Limited independent reviews available compared to larger competitors

Best For

Two types of patients:

1. Patients who cannot or prefer not to self-inject. BreezeMeds offers oral formulations for both semaglutide and tirzepatide. This is a genuine differentiator — most GLP-1 providers offer injectable options only. Patients with needle aversion, injection-site reactions, or injection-related anxiety have limited alternatives. The oral premium ($299–$399/mo) is real, but the oral pathway is not widely available elsewhere in the compounded market.

2. Patients who value institutional transparency. Published physician names and published pharmacy partnerships are uncommon among telehealth GLP-1 providers. For patients who want to know who is medically overseeing their care and which pharmacy is preparing their medication, BreezeMeds provides that information upfront.

Not ideal for: Patients who need medication within the first week of enrollment (the 2–3 week timeline is a real barrier), or patients primarily driven by lowest possible cost (injectable options are available more cheaply elsewhere).

Editorial Verdict

BreezeMeds occupies a real niche: oral GLP-1 formulations combined with above-average institutional transparency. The named medical directors and named pharmacy partners are a departure from the typical telehealth GLP-1 model where these details are obscured or absent.

The delivery timeline is the primary practical friction point. A 2–3 week wait from consultation to medication is meaningfully longer than the ~1 week most competitors deliver in. Patients who have done their research and are ready to start will notice this.

The oral formulations are worth the premium only if the patient genuinely cannot or should not inject. Oral GLP-1 bioavailability differs from injectable, and compounded oral formulations are even less studied than compounded injectables. Patients considering oral options should discuss the pharmacological differences with the prescribing provider.

The regulatory context is the same as for any compounded GLP-1 platform: these medications are not FDA-approved, and the FDA is actively pressuring the compounding sector as of April 2026. BreezeMeds' multiple pharmacy partnerships offer some supply resilience, but they do not change the fundamental regulatory uncertainty.

Bottom line as of April 2026: BreezeMeds is worth considering if the oral formulation is the deciding factor or if named-physician transparency matters to you. For standard injectable semaglutide or tirzepatide, there are faster and often cheaper alternatives.

Related Content

• Best GLP-1 Weight Loss Programs 2026 — All providers ranked
• GLP-1 Compounding Pharmacies: What Patients Need to Know — Full regulatory context
• GLP-1 Cost & Insurance FAQ — What you'll actually pay